MAP2K1 and melanoma: The impact of combined MEK1/2 and p110β inhibition was most pronounced in the WM266.4 line and ineffective in a further panel of additional human melanoma lines carrying BRAF and PTEN mutations, namely UACC62, SKMEL28, and WM793 (Supplementary Fig. S6A–S6C).